Overview

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

Status:
Completed
Trial end date:
1996-06-01
Target enrollment:
Participant gender:
Summary
The objectives of the study were: - To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. - To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Trio Medicines Ltd.
Collaborator:
Ferring Pharmaceuticals
Treatments:
Gastrins